Tim Anderson
Stock Analyst at B of A Securities
(1.83)
# 2,951
Out of 4,825 analysts
33
Total ratings
50%
Success rate
2.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $590.00 | -7.29% | 2 | Apr 17, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $171 → $159 | $154.46 | +2.94% | 5 | Apr 10, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $11.25 | +131.11% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $103.25 | +22.03% | 2 | Mar 5, 2025 | |
| AMGN Amgen | Maintains: Underperform | $275 → $294 | $283.78 | +3.60% | 4 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $193.34 | +15.34% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $23.44 | +62.12% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $27.03 | +25.79% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $83.26 | +34.52% | 4 | Feb 5, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $29 | $23.93 | +21.19% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $49.61 | +26.99% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $120.93 | +47.19% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $794.10 | +25.55% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $111.23 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $70.51 | - | 1 | Sep 22, 2017 |
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $590.00
Upside: -7.29%
Johnson & Johnson
Apr 10, 2025
Maintains: Neutral
Price Target: $171 → $159
Current: $154.46
Upside: +2.94%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $11.25
Upside: +131.11%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $103.25
Upside: +22.03%
Amgen
Mar 5, 2025
Maintains: Underperform
Price Target: $275 → $294
Current: $283.78
Upside: +3.60%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $193.34
Upside: +15.34%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $23.44
Upside: +62.12%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $27.03
Upside: +25.79%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $83.26
Upside: +34.52%
Pfizer
Dec 10, 2024
Reinstates: Neutral
Price Target: $29
Current: $23.93
Upside: +21.19%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $49.61
Upside: +26.99%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $120.93
Upside: +47.19%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $794.10
Upside: +25.55%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $111.23
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $70.51
Upside: -